NeurogesX' second most advanced product candidate, NGX-1998, is a topically applied, liquid formulation containing a high concentration of capsaicin designed to treat pain associated with neuropathic pain conditions. NGX-1998 is currently in Phase 1 development.
NeurogesX' early stage product pipeline includes pre-clinical compounds which are prodrugs of acetaminophen and various opioids. The company has evaluated these compounds in vitro and in vivo and is currently seeking development partners for these programs.
Safe Harbor Statement
This press release contains forward-looking statements for purposes of
the Private Securities Litigation Reform Act of 1995 (the "Act"). NeurogesX
disclaims any intent or obligation to update these forward-looking
statements, and claims the protection of the Safe Harbor for
forward-looking statements contained in the Act. Examples of such
statements include, but are not limited to, the potential markets for
NeurogesX' product candidates; the expected benefits of NeurogesX' product
candidates; and its plans with regard to seeking potential development
partners for its early stage product pipeline. Such statements are based on
management's current expectations, but actual results may differ materially
due to various risks and uncertainties, including, but not limited to,
NeurogesX' product candidates may have unexpected adverse side effects or
inadequate therapeutic efficacy; positive results in clinical trials may
not be sufficient to obtain FDA or European re
|SOURCE NeurogesX, Inc.|
Copyright©2008 PR Newswire.
All rights reserved